FDA declines to approve Allergan’s Esmya

Share this post

Allergan Plc said on Tuesday U.S. health regulators had declined to approve Esmya, its treatment for abnormal uterine bleeding in women with uterine fibroids, requesting more information and citing safety issues outside the United States.

This post was syndicated from Reuters: Health News. Click here to read the full text on the original website.

Share this post

Be the first to comment

Leave a Reply